Acute improvement of peripheral endothelial function in postmeno- pausal women with coronary artery disease after single oral intake of 17β-estradiol valerate
| Autor: | M.D. Enderle, H.U. Haering, R. Sayer, R. Haasis, M. Pfohl, Christoph Meisner, B. Balletshofer, A. O. Mück |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
medicine.medical_specialty
medicine.drug_class Endocrinology Diabetes and Metabolism Blood Pressure Coronary Disease Placebo Coronary artery disease Angina Endocrinology Internal medicine Internal Medicine medicine Humans Endothelial dysfunction Aged Ultrasonography Estrogens Conjugated (USP) Estradiol business.industry Estradiol valerate General Medicine Middle Aged medicine.disease Vasoprotective Postmenopause Vasodilation Blood pressure Estrogen Female Endothelium Vascular business medicine.drug |
| Zdroj: | Experimental and Clinical Endocrinology & Diabetes. 108:382-385 |
| ISSN: | 1439-3646 0947-7349 |
| DOI: | 10.1055/s-2000-8133 |
| Popis: | Chronic estrogen supplementation is known to improve endothelial function in postmenopausal women. We studied the acute effect of a single dose of orally administered 17beta-estradiol valerate (E2) on the peripheral endothelial dependent and independent vasodilatation in postmenopausal women with coronary artery disease (CAD). 20 postmenopausal women (age: 64.9 (7.2) y, height: 1.61 (0.04) m. weight: 68.6 (10.6) kg) with angiographically confirmed CAD were randomly examined for flow-associated vasodilatation (= FAD%, a marker for endothelial dependent vasodilatation) and for glyceryltrinitrate (400 microg, p.o.) induced vasodilatation (= GTN%, representing endothelial independent vasodilatation) two hours after placebo controlled, randomized crossover intake of 4 mg E2 p.o. After placebo FAD% was impaired (3.5 (1.7)%) compared to historic controls. After the oral intake of 4 mg E2, FAD% improved to 5.0 (2.8)% (P=0.02). GTN% was not significantly influenced by the oral E2 (E2: 12.6 (5.7) v placebo: 11.2 (6.9)%, P=0.14). Endothelial dysfunction can partially be restored by a single oral dose of 4 mg E2. This indicates an acute vasoprotective effect of E2 beyond its genomic and lipid modifying actions. It remains to be investigated if estrogen might play a beneficial role in the acute treatment of symptomatic coronary artery disease such as angina pectoris or preinfarct syndrome. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|